一种新型PTPN1剪接变异体上调经典型霍奇金淋巴瘤细胞中的JAK/STAT活性
经典型霍奇金淋巴瘤(cHL)中JAK/STAT持续激活的机制尚未完全阐明。本研究在cHL细胞系和原发肿瘤样本中鉴定出缺失外显子序列的截短型PTP1B mRNA变异体,其中缺失外显子6的剪接变异体PTP1BΔ6在血清刺激后表达显著增加,可增强干扰素-γ和白细胞介素-4诱导的JAK/STAT活性及基础STAT活性,并促进cHL细胞增殖、差异性降低吉西他滨和依托泊苷的细胞毒性作用。
要点
- 在cHL细胞系和原发肿瘤样本中鉴定出缺失1个或数个外显子序列的截短型PTP1B mRNA变异体。
- PTP1BΔ6在cHL细胞系中低水平表达,血清刺激后表达显著增加。
- PTP1BΔ6增强干扰素-γ和白细胞介素-4诱导的JAK/STAT活性及基础STAT活性。
核心结论
- PTP1BΔ6是cHL中JAK/STAT信号的正向调节因子。
研究设计与样本
- 在cHL细胞系和原发cHL肿瘤样本中检测PTP1B mRNA变异体表达。
- 在HEK293或HEK293-STAT6细胞及稳定转染的L-428和U-HO1 cHL细胞系中进行PTP1BΔ6功能鉴定。
主要发现
- cHL细胞系和原发cHL肿瘤样本中表达缺失1个或数个外显子序列的截短型PTP1B mRNA变异体。
- PTP1BΔ6在cHL细胞系中低水平表达,血清刺激cHL后PTP1BΔ6表达显著增加。
- PTP1BΔ6对HEK293或HEK293-STAT6细胞中干扰素-γ和白细胞介素-4诱导的JAK/STAT活性有正向作用。
- PTP1BΔ6对稳定转染的L-428和U-HO1 cHL细胞系中基础STAT活性有正向作用。
- PTP1BΔ6表达增加L-428和U-HO1细胞增殖,并差异性降低吉西他滨和依托泊苷的细胞毒性作用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic activation of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathways is a hallmark of a variety of B-cell lymphomas, including classical Hodgkin lymphoma (cHL). Constitutive JAK/STAT signaling is crucial for survival and proliferation of Hodgkin/Reed-Sternberg (HRS) cells, the malignant cells of cHL. Although the molecular basis of this constitutive JAK/STAT signaling in cHL has not been completely understood, accumulating reports highlight the role of an inactivation or reduced expression of negative JAK/STAT regulators such as silencer of cell signaling 1 (SOCS1) or protein-tyrosine phosphatase 1B (PTP1B) in this process. Here, we report the expression of truncated PTP1B mRNA variants identified in cHL cell lines and primary cHL tumor samples lacking either 1 or several exon sequences. One of these novel PTP1B variants, a splice variant lacking exon 6 (PTP1BΔ6), was found expressed at low levels in cHL cell lines. However, serum stimulation of cHL augmented the expression of PTP1BΔ6 significantly. Functional characterization of PTP1BΔ6 revealed a positive effect on interferon-γ- and interleukin-4-induced JAK/STAT activity in HEK293 or HEK293-STAT6 cells, and on the basal STAT activity in stably transfected L-428 and U-HO1 cHL cell lines. Furthermore, PTP1BΔ6 expression increased the proliferation of L-428 and U-HO1 cells and reduced cytotoxic effects of the chemotherapeutical agents gemcitabine and etoposide distinctively. Collectively, these data indicate that PTP1BΔ6 is a positive regulator of JAK/STAT signaling in cHL.
引用
- Zahn M, Marienfeld R, Melzner I, et al. A novel PTPN1 splice variant upregulates JAK/STAT activity in classical Hodgkin lymphoma cells. Blood. 2017. PMID: 28082443. doi:10.1182/blood-2016-06-720516
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。